摘要
目的 :探讨mdm2癌基因蛋白在骨巨细胞瘤 (GCT)的表达及与GCT病理分级和临床良恶性的关系。方法 :应用SP免疫组织化学方法检测mdm2在 5 2例GCT(GCT按Jaffe分级 :Ⅰ级 15例、Ⅱ级 2 5例、Ⅲ级 12例 )中的表达。结果 :18例mdm2表达呈阳性 ,占 34 .6 % ,在Ⅰ～Ⅲ级中的阳性表达率分别为 40 .0 %、32 .0 %、33.3% ,mdm2阳性表达率在骨巨细胞瘤Ⅰ～Ⅲ级中的差异无显著性意义 (χ2 =0 .2 8,P >0 .0 5 )。在良性、可疑恶性和恶性中的阳性表达分别为 15 .0 %、35 .3%、6 0 .0 % ,mdm2阳性表达率在骨巨细胞瘤良恶性中的差异有显著性意义 (χ2 =7.6 7,P <0 .0 5 )。结论 :mdm2在GCT中的表达与病理分级无关而与其临床良恶性程度有关。
Objective: To investigate the relationship of mdm2 protein overexpression with pathological types and prognosis of human giant cell tumor of bone. Methods: Monoclonal antibodies directed against mdm2 proteins were used to measure the expression of these proteins in the nuclear of cells from the sections of giant cell tumor of bone. Results: Eighteen of 52 tumors expressed mdm2 protein. According to Jaffe's grading the positive percentages of grade Ⅰ , grade Ⅱ and grade Ⅲ giant cell tumors of bone were 40% , 32% and 33.3% respectively. A positive correlation existed between the prognosis and mdm2 protein positivity. However, there was no relationship between mdm2-positive cases and pathological types of the tumor. Conclusion: There was a statistically significant correlation between the expression of mdm2 protein and the prognosis of giant cell tumor of bone (χ 2=7.67, P <0.05). However, there was no statistically significant correlation between the expression of mdm2 and the pathological types of giant cell tumor of bone ( χ 2=0.28, P >0.05).
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2000年第4期262-264,共3页
Chinese Journal of Clinical Oncology
基金
湖南省科委科研基金
